Precision Therapy Versus Standard Therapy in AML and MDS in Elderly

This is a randomized clinical trial that randomizes between treatment principles. The study will investigate if precision therapy determined by a tumour board is better than standard treatment for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in elderly. The tumour board will decide the precision therapy based on identified genetic changes that can guide customized therapy. There are currently 40-50 targeted therapies approved for various cancers in Norway. The precision therapy will be given in addition to the standard treatment. The primary study objective will be to evaluate the cost-effectiveness of a precision therapy strategy compared with standard treatment. Other objectives will mesaure efficacy and satety of the treatment, and impact on life quality of the patients.

NCT Number	NCT05025098
Lead Sponsor	University Hospital, Akershus
Conditions	AML, Adult, MDS
Enrollment	36 participants
Start Date	2021-06-22
Primary Completion	2026-06-10 (estimated)
Study Completion	2027-06-10 (estimated)
Updated on ClinicalTrials.gov	2021-08-27